2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responses
2016
Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide
Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA. Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide. Diabetes Care 2016, 39: 1127-1134. PMID: 27208332, PMCID: PMC4915555, DOI: 10.2337/dc16-0089.Peer-Reviewed Original ResearchConceptsAdjunctive agentsInsulin deliveryTotal daily insulin doseWeight lossDose escalation periodClosed-loop insulin deliveryDaily insulin dosePlasma glucose excursionsLoop insulin deliveryPrandial insulin deliveryContent of mealsConcomitant bluntingLiraglutide therapyDose titrationLiraglutide treatmentDose escalationInsulin doseGlycemic excursionsGlucose excursionsPostprandial hyperglycemiaPostprandial incrementLiraglutidePramlintideBeneficial effectsEscalation period
2015
Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes
Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal Of Diabetes Science And Technology 2015, 9: 639-643. PMID: 25883166, PMCID: PMC4604546, DOI: 10.1177/1932296815578881.Peer-Reviewed Original ResearchConceptsRapid-acting insulin analoguesType 2 diabetesMeal tolerance testPlasma insulin levelsInsulin analoguesInsulin levelsGlucose excursionsInjection siteInsulin absorptionType 2 diabetic patientsPostmeal glucose excursionsStandardized liquid mealPostprandial glucose excursionsTime-action profilePostprandial glucose controlInsulin therapyDiabetic patientsGlucose controlLiquid mealOvernight fastInsulin aspartTolerance testPostprandial hyperglycemiaPremeal bolusesPremeal injections
2005
Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes
Doyle Boland EA, Steffen AT, Tamborlane WV. Contrasting Challenges of Insulin Pump Therapy in a Toddler and Adolescent With Type 1 Diabetes. The Science Of Diabetes Self-Management And Care 2005, 31: 584-590. PMID: 16100334, DOI: 10.1177/0145721705278888.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesGlycemic controlCSII therapyHypoglycemic episodesInsulin bolus dosesHemoglobin A1c levelsPediatric diabetes clinicSevere hypoglycemic episodesInsulin pump therapySubcutaneous insulin infusionYears of ageAge 13 yearsA1c levelsCatheter siteDiabetes clinicBolus dosesPump therapyDaily injectionsIdeal therapyInsulin infusionInsulin injectionsPostprandial hyperglycemiaFood intakePump use